Latest Conference Articles

December 12th 2023, 2:00pm

OncLive News Network: On Location at ASH 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

December 12th 2023, 1:32am

ASH Annual Meeting and Exposition

The high-precision cellular product Orca-Q demonstrated early signals of clinical activity as well as an acceptable safety profile for patients undergoing haploidentical stem cell transplantation without posttransplant cyclophosphamide.

December 12th 2023, 12:09am

ASH Annual Meeting and Exposition

David J. Andorsky, MD, discusses recently observed patterns of care with BTK inhibitors in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in the community setting in the United States, and how social determinants of health may have affected these outcomes.

December 12th 2023, 12:05am

ASH Annual Meeting and Exposition

Raajit K. Rampal, MD, PhD, discusses findings from the phase 3 MANIFEST-2 trial investigating pelabresib in combination with ruxolitinib for JAK inhibitor–naive patients with myelofibrosis.

December 11th 2023, 11:34pm

ASH Annual Meeting and Exposition

The combination comprised of zanubrutinib, obinutuzumab, and venetoclax elicited high response rates and 2-year progression-free survival rates that compared favorably with historical outcomes achieved with chemoimmunotherapy in high-risk patients with previously untreated mantle cell lymphoma harboring TP53 mutations.

December 11th 2023, 8:58pm

ASH Annual Meeting and Exposition

Patients with B-cell malignancies who were intolerant to treatment with acalabrutinib experienced clinically meaningful benefits when treated with zanubrutinib, suggesting zanubrutinib may be a viable treatment option for this population.

December 11th 2023, 8:56pm

ASH Annual Meeting and Exposition

Pelabresib plus ruxolitinib demonstrated a 35% or greater reduction in spleen volume and trended toward reducing mean absolute total symptom score (TSS) as well as improving TSS reduction by 50% at 24 weeks in patients with JAK inhibitor–naive myelofibrosis.

December 11th 2023, 8:05pm

ASH Annual Meeting and Exposition

Patients with relapsed/refractory follicular lymphoma experienced durable responses when treated with tisagenlecleucel (Kymriah) in the phase 2 ELARA study (NCT03568461), according to data presented at the 2023 ASH Annual Meeting.

December 11th 2023, 7:52pm

ASH Annual Meeting and Exposition

Treatment with ruxolitinib led to prolonged failure-free survival and improved disease control vs best available treatment in patients with either steroid-refractory or -dependent chronic graft-vs-host disease.

December 11th 2023, 7:51pm

ASH Annual Meeting and Exposition

The phase 1a/1b NX-1607-101 trial will evaluate NX-1607, a CBL-B inhibitor, in patients with advanced malignancies, including diffuse large B-cell lymphoma.

December 11th 2023, 7:42pm

ASH Annual Meeting and Exposition

Treatment with single-agent pirtobrutinib showed encouraging efficacy with a tolerable safety profile in a cohort of heavily pretreated patients with relapsed/refractory follicular lymphoma.

December 11th 2023, 6:51pm

ASH Annual Meeting and Exposition

Oral iptacopan (Fabhalta) monotherapy induced durable responses and hemolysis control in patients with paroxysmal nocturnal hemoglobinuria and persistent anemia who had previously received anti-C5 treatment.

December 11th 2023, 6:41pm

ASH Annual Meeting and Exposition

Brentuximab vedotin plus nivolumab, doxorubicin, and dacarbazine was found to have efficacy and acceptable safety and tolerability when used as a frontline treatment in patients with previously untreated advanced, classical Hodgkin lymphoma.

December 11th 2023, 5:39pm

ASH Annual Meeting and Exposition

Acalabrutinib, as monotherapy or in combination with obinutuzumab, continued to improve progression-free survival vs obinutuzumab and chemotherapy in patients with treatment-naive chronic lymphocytic leukemia, regardless of genomic marker status.

December 11th 2023, 2:00pm

OncLive News Network: On Location at ASH 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

December 11th 2023, 3:22am

ASH Annual Meeting and Exposition

The combination of Isa-KRd significantly increased the rates of minimal residual disease negativity at cutoffs post-consolidation vs KRd in patients with newly diagnosed multiple myeloma.

December 11th 2023, 3:12am

ASH Annual Meeting and Exposition

Axatilimab induced rapid and durable responses with an acceptable toxicity profile at all doses analyzed with highest efficacy observed at the 0.3-mg/kg dose in patients with recurrent or refractory chronic graft-vs-host disease.

December 10th 2023, 11:55pm

ASH Annual Meeting and Exposition

Susan Bal, MD, discusses updated safety and efficacy data from a phase 1 study evaluating the GPRC5D-targeted autologous CAR T-cell therapy BMS-986393 in relapsed/refractory multiple myeloma, including in patients with prior BCMA-directed therapy.

December 10th 2023, 11:52pm

ASH Annual Meeting and Exposition

Paolo Ghia, MD, PhD, full professor, discusses a biomarker subgroup analysis of the phase 3 SEQUOIA trial investigating zanubrutinib vs bendamustine plus rituximab in patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma without 17p deletions.

December 10th 2023, 11:50pm

ASH Annual Meeting and Exposition

Oral decitabine/cedazuridine and parenteral hypomethylating agents were associated with similar levels of comorbidities and disease burden in patients with myelodysplastic syndrome.